I know some folks have been to Dr. Marek ...
This will be another resource for MSA folks ........
I believe this shows that there is promise for more help with neurogenerative disorders - (these docs wouldn't leave otherwise)
and, perhaps, they have to start their own center because Yale has so much gov. support that might be endangered by any trial that the docs feel are promising (only an opinion - but knowing how skittish institutions are about grants and politics ;-).........
cheers,
Sheila
Yale profs to start brain research center
[INLINE]
[INLINE]
[INLINE]
Abram Katz, Register Science Editor June 08, 2001
[INLINE]
[INLINE]
[INLINE]
NEW HAVEN -- Two top Yale scientists are leaving the university to start a non-profit center where they hope to accelerate research into Parkinson's disease and other brain-destroying diseases.
The new Institute for Neurodegenerative Disorders and associated Molecular NeuroImaging company will continue several ongoing studies into the mysteries of neurons.
The center, at 60 Temple St., will be funded by grants from private foundations, pharmaceutical companies and the federal government.
Dr. Kenneth Marek, president of the institute, said he believes medications that can halt, or even reverse, the effects of Parkinson's could be ready in about three years.
The institute will also concentrate on dystonia and Huntington's disease, and eventually possibly Alzheimer's disease.
"Now there is no way to slow or treat Parkinson's disease. We're on the brink of finding a treatment -- stopping progression, and possibly restoring function," Marek said.
"This will change how we look at these diseases entirely," he said.
Marek, who was director of the Movements Disorder Center at Yale University for 10 years, said the institute will concentrate on clinical, patient-oriented research.
"We wanted to work more rapidly.
I found after many years at Yale that we could be more efficient and flexible if we do research independently," Marek said.
Hiring, establishing research protocols, securing contracts with pharmaceutical companies and applying for federal grants will all be streamlined at the institute, Marek said.
Marek and Dr. John P. Seibyl, executive director of the institute, who until the end of July ischief of Nuclear Medicine at Yale, already had quarters at 60 Temple St.
Marek and Seibyl said their departure should not be construed as criticism of Yale.
Irwin Birnbaum, chief operating officer of the Yale School of Medicine, said, "Although this program is not affiliated with the Yale School of Medicine, it builds upon the important basic research and clinical services developed at Yale."
The institute will judge experimental treatments by using single photon emission computerized tomograpy, or SPECT, to check the brains of Parkinson's patients.
Joan LaRose, 60, of Southington, was diagnosed with Parkinson's in 1995 and is among the patients being seen at the institute.
Research lends value to an otherwise bleak condition, she said.
"This puts the disease to the best benefit. It gives you some sense of control," LaRose said.
During SPECT, a protein similar to cocaine and tagged with radioactive iodine is injected into the patient. The cocaine-like molecule is useful because, like cocaine, it has a high affinity for the dopamine system in the brain. The protein, called beta-CIT, seeks out and locks onto dopamine-making neurons.
Parkinson's is characterized by progressive loss of dopamine neurons, which leads to tremor and loss of muscle control.
In less clinical terms, "Parkinson's disease feels like your body is doing things you don't want it to do -- moving when you want to stay still -- or holding still when you want it to move," said Jackie Dorwin, 51, who was diagnosed in 1992.
"We're lab rats," said Dworin, who is on the institute's board of directors.
The SPECT machine's three load-shielded detectors sense individual rays of radioactivity emanating from the dopamine receptors.
A computer takes the data and constructs an image that displays dopamine cells as bright pixels.
A healthy brain shows two bright ovals. A person with Parkinson's has darker or smaller areas.
Seibyl, who is also head of Yale's NeuroSPECT Center through the end of the month, said his departure from the university would free him from administrative duties and allow him to concentrate on research.
About 300 patients in 55 sites in the United States and Canada are currently enrolled in studies that bring them to the Temple Street center.
The institute is participating in studies on:
o The long-term effects of the Parkinson's medicine L-dopa. Some scientists suspect it may increase the rate of progression of the disease.
o Twins, in which one or both, have Parkinson's. This should help define the genetic component of the disease.
o Environmental exposures that might be linked with Parkinson's.
Marek and colleagues will examine workers in Albany, N.Y., who were exposed to high levels of PCBs to see if they have a higher rate of Parkinson's.
Among treatment studies are:
o Anti-oxidants. Some researchers suspect that brain cell metabolism creates highly reactive oxidant compounds and that damage accrues into Parkinson's.
o Glutamate antagonists.
Damaged neurons secrete glutamate.
High levels of glutamate damage additional cells. Blocking glutamate might preserve the brain.
o "JNK" inhibitors. Cells self-destruct when damaged in a process called apoptosis. Out of control apoptosis could, theoretically, cause Parkinson's. JNK inhibitors interfere with apoptosis.
o Neuroimmunophilins are small molecules that cross the blood-brain barrier into the brain. They can be taken orally. Research suggests that they might help re-grow lost neurons.
About 1 million people in the U.S.
have Parkinson's disease and 60,000 new cases appear every year. At age 65 a person faces a 2 percent risk of Parkinson's, Marek said.
İNew Haven Register 2001
[INLINE]
cheers
sheila
Too often we underestimate the power of a touch, a smile, a kind word, a listening ear .... all of which have the potential to turn a life around. --- Leo Buscaglia